Abemaciclib is a selective cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used in the management of hormone receptor positive (HR +), human epidermal growth factor receptor 2 negative (HER2-) unresectable or recurrent breast cancer. Here, CDK4 is linked to breast cancer.